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ABSTRACT
Sesquiterpene lactones (SLs) are the active constituents of a variety of medicinal 
plants and found to have potential anticancer activities. However, the intracellular 
molecular targets of SLs and the underlying molecular mechanisms have not been well 
elucidated. In this study, we observed that EM23, a natural SL, exhibited anti-cancer 
activity in human cervical cancer cell lines by inducing apoptosis as indicated by 
caspase 3 activation, XIAP downregulation and mitochondrial dysfunction. Mechanistic 
studies indicated that EM23-induced apoptosis was mediated by reactive oxygen 
species (ROS) and the knockdown of thioredoxin (Trx) or thioredoxin reductase (TrxR) 
resulted in a reduction in apoptosis. EM23 attenuated TrxR activity by alkylation of 
C-terminal redox-active site Sec498 of TrxR and inhibited the expression levels of 
Trx/TrxR to facilitate ROS accumulation. Furthermore, inhibition of Trx/TrxR system 
resulted in the dissociation of ASK1 from Trx and the downstream activation of JNK. 
Pretreatment with ASK1/JNK inhibitors partially rescued cells from EM23-induced 
apoptosis. Additionally, EM23 inhibited Akt/mTOR pathway and induced autophagy, 
which was observed to be proapoptotic and mediated by ROS. Together, these results 
reveal a potential molecular mechanism for the apoptotic induction observed with SL 
compound EM23, and emphasize its putative role as a therapeutic agent for human 
cervical cancer.
INTRODUCTION
Thioredoxin reductase (TrxR) is a ubiquitously 
expressed oxidoreductase crucial for maintaining 
cellular redox homeostasis by counteracting the effects 
of reactive oxygen species (ROS) and regulating redox-
related signaling cascades [1]. TrxR is the only enzyme 
known to catalyze the reduction of thioredoxin (Trx), 
which participates in wide variety of cellular processes 
including the oxidative stress response, gene regulation 
via the NF-κB, p53, and Ref-1 transcription factors, and 
the competitive inhibition of apoptosis-regulating signal 
kinase 1 (ASK1)-induced apoptosis [2].
Elevated Trx/TrxR activity was found to be involved 
in the development and progression of cancer [3, 4]. 
Notably, over expression of Trx/TrxR can promote cancer 
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cell proliferation and has been associated with tumor 
angiogenesis, invasion, and metastasis [5]. Furthermore, 
the Trx/TrxR system contributes to tumor cell resistance 
to oxidative stress-induced apoptosis [6], which is an 
important mechanism of various anticancer agents. 
In addition, knock down of TrxR expression nearly 
abolished the capacity of lung cancer cells to form tumors 
in a xenograft model system [7]; over expression of the 
alternative splicing variant of TrxR induced apoptosis 
in HeLa cells [8]. Overall, these studies substantiate the 
notion that mammalian TrxR may be a promising drug 
target for cancer therapy.
The C-terminal active site of mammalian TrxR 
has a conserved sequence, -Gly-Cys-Sec-Gly-COOH, 
which contains an active selenocysteine. During 
catalysis, electrons are transferred from NADPH to the 
N-terminal active site of TrxR, where they are delivered 
to the C-terminal redox-active sites (Cys497 and Sec498) [9]. 
Then, TrxR can subsequently reduce various substrates, 
including the disulfide active site of Trx. The inhibitory 
effects of many active compounds and drugs targeting 
mammalian TrxR are mainly based on their interactions 
with the Sec498 residue. Prominent examples include gold- 
and platinum-based compounds [10], arsenic trioxide [11], 
curcumin [12], and natural flavonoids [13].
Sesquiterpene lactones (SLs) are the active 
constituents of a variety of medicinal plants. In recent 
years, the anticancer activity of SLs has attracted a great 
deal of interest and extensive research has been carried 
out to illuminate their anticancer properties [14]. SLs have 
been reported to inhibit proliferation, migration, invasion 
and induce apoptosis in various tumor cells, such as lung 
cancer [15], breast cancer [16], melanoma [17], leukaemia 
[18], and colorectal cancer [19]. Main molecular events 
involved in these SLs-specific activities were investigated 
to be inhibition of NF-κB activation, suppression of anti-
apoptotic proteins, and blockage of PI3K/Akt and JAK2/
STAT3 signaling [19–22]. However, the intracellular 
molecular targets of SLs have not been well elucidated 
and continued work is needed to identify the mechanisms 
underlying the potential function of SLs in cancer therapy.
In this study, we demonstrate the anticancer 
activity of EM23, a natural SL family member isolated 
from Elephantopus mollis, in the CaSki and SiHa human 
cervical cancer cell lines. Mechanistically, we demonstrate 
that EM23 specifically targets the mammalian TrxR by 
alkylating the C-terminal redox-active site Sec498 of this 
enzyme. EM23-induced ROS accumulation and ASK1/
JNK signal activation are critical for the induction of 
apoptosis. Furthermore, EM23 treatment also facilitates 
autophagy, which contributes to the post-treatment 
apoptosis observed in CaSki and SiHa cells.
RESULTS
Growth inhibitory effect of EM23 on human 
cancer cell lines
The chemical structure of EM23 is shown in 
Figure 1A. To determine the effect of EM23 on the cellular 
growth inhibition, several human cancer cell lines were 
treated with varying concentrations of EM23 for 24 h, 
including lung cancer cell line A549; human breast cancer 
cell line MCF-7; human esophageal cancer cell lines TE-1, 
EC109, and EC9706; human cervical cancer cell lines 
CaSki and SiHa; and human leukemia cell lines HL-60 
and K562. Cell viability was assessed by MTT assay. As 
shown in Figure 1B, EM23 exhibited the most significant 
growth inhibitory activities on cervical CaSki and SiHa 
cell lines. The IC
50
 values of EM23 for CaSki and SiHa 
cells were 5.8 and 6.6 μM, respectively. In contrast, 
significantly lesser loss of cell viability due to treatment 
with EM23 was observed on human cervical epithelial 
Ect1/E6E7 cell line (Supplementary Figure S1). The IC
50
 
value of EM23 for Ect1/E6E7 cells was 85.5 μM, which 
was approximately 15-fold and 13-fold higher than that 
of for CaSki and SiHa cells, respectively. The molecular 
mechanism(s) underlying the effects of EM23 on the 
human cervical cancer cell lines was next investigated.
EM23 induces cell cycle arrest and apoptosis in 
CaSki and SiHa cells
To examine the mechanism underlying the 
inhibitory effects of EM23 on cell growth, the cell cycle 
phase distributions of EM23-treated CaSki and SiHa cells 
were analyzed by flow cytometry. Notably, an increase 
in the G2/M population was observed in cells following 
treatment with EM23, as treatment with 20 μM EM23 
increased the G2/M population of CaSki and SiHa cells by 
29% and 13%, respectively, as compared to control groups 
(Figure 1C).
To investigate EM23-induced apoptotic cell death, 
both cell lines were treated with increasing concentrations 
of EM23 for 24 h and stained with Annexin-V-FITC/
PI. The resulting apoptotic ratios were analyzed by 
flow cytometry. As shown in Figure 1D, EM23 elicited 
apoptosis in a dose-dependent manner in both cell lines, 
as treatment with 20 μM EM23 resulted in 60% and 87% 
cell death in CaSki and SiHa cells, respectively. The 
TUNEL assay for observation of apoptotic DNA cleavage 
also confirmed EM23-induced apoptosis (Supplementary 
Figure S2).
EM23 induces caspase 3 activation and 
mitochondrial dysfunction 
We next analyzed the effect of EM23 on 
caspase 3 activation, PARP cleavage, and XIAP 
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protein expression. Significantly, western bloting 
analysis revealed that EM23 induced caspase 3 
cleavage, and downregulated the expression level 
of pro-caspase 3 (Figure 2A). PARP, a DNA-repair 
enzyme, is a known substrate of caspase 3 [23]; 
therefore, we examined PARP degradation following 
EM23 treatment. As shown in Figure 2A, PARP 
underwent specific proteolytic cleavage as suggested by 
the generation of the 89 kDa PARP fragment in CaSki 
cells treated with EM23 at 5, 15 and 20 μM and in SiHa 
cells treated with EM23 at 15 and 20 μM, respectively. 
In addition, the expression level of XIAP, the most 
potent human IAP protein that can inhibit the activity of 
caspase 3 was observed to decrease with EM23 treatment 
in a dose-dependent manner.
Mitochondria play a central role in the intrinsic 
apoptosis pathway. The loss of mitochondrial membrane 
potential (MMP; Δψm) is regarded as a hallmark of cell 
apoptosis that occurs prior to caspase activation [24]. As 
shown in Figure 2B, EM23 treatment significantly disrupted 
the Δψm in both cell lines, as demonstrated in a shift from 
red to green. Notably, the relative percentage of fluorescence 
green cells increased by 54% and 35% in CaSki and SiHa 
cells, respectively, following treatment with 20 μM EM23. 
Figure 1: EM23 induced cell apoptosis and cell cycle arrest. (A) Chemical structure of EM23. (B) Effects of EM23 on the growth 
of the following human cancer cell lines: lung cancer cell line A549; breast cancer cell line MCF-7; esophageal cancer cell lines TE-1, 
EC109, and EC9706; cervical cancer cell lines CaSki and SiHa; and leukemia cell lines HL-60 and K562. Cells were treated with various 
concentrations of EM23 for 24 h, and cell viability was measured by MTT assay. (C) Effects of EM23 on cell cycle distribution. CaSki 
and SiHa cells were treated with 0, 5, 15, and 20 µM EM23 for 24 h, and cell cycle distribution was measured by flow cytometry after 
PI staining. (D) Induction of apoptosis by EM23 in CaSki and SiHa cells. Cells were treated as above and index of apoptotic cells were 
analyzed by flow cytometry after Annexin-V-FITC/PI staining. All data are presented as the mean ± SD of three independent experiments. 
*P < 0.5 and **P < 0.01.
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EM23 induced-ROS generation is involved in its 
anticancer activity
Mitochondria are the main source of ROS, and excess 
ROS accumulation elicits oxidative stress that can cause 
prominent damage to DNA, lipids, and proteins within the 
cell to subsequently induce apoptosis [25]. To investigate the 
role of ROS generation on the anticancer activity of EM23, 
we first examined intracellular ROS production in EM23-
treated CaSki and SiHa cells using DCFH-DA. As shown 
in Figure 3A, EM23 caused a remarkable accumulation of 
ROS in CaSki and SiHa cells, particularly following the 
4 and 2 h treatments, respectively. Notably, pretreatment 
with NAC, a ROS scavenger, almost completely rescued 
EM23-induced apoptosis in both cell lines, indicating that 
ROS accumulation is involved in EM23-induced apoptosis 
(Figure 3B and 3C). Furthermore, EM23 induced Δψm 
disruption was also completely rescued by NAC pre-
treatment (Figure 3D).
EM23 inhibits the activity of TrxR in cell-free 
systems
To investigate the effects of EM23 on TrxR activity, 
NADPH-reduced TrxR was incubated with EM23 in cell-
free system. As shown in Figure 4A, TrxR activity was 
inhibited by EM23 in a dose-dependent manner with 
an IC
50
 value of 7.8 μM as determined by DTNB assay. 
In addition, EM23-induced TrxR inactivation was also 
positively correlated with incubation time (Figure 4B). 
TrxR activity was almost completely inhibited by EM23 
after 90 min of incubation. These results identify EM23 as 
an effective TrxR inhibitor.
EM23 attenuates TrxR activity by binding the 
selenocysteine site
The three-dimensional crystal structure of 
mammalian TrxR revealed two redox-active sites (Cys497 
and Sec498) located on the flexible C-terminal arm of the 
enzyme [9]. In its reduced form, TrxR-Cys497 and -Sec498 
were present as –SH and –SeH groups, respectively. It 
has been reported that both –SH and –SeH groups can be 
alkylated at high pH (pH 8.5), while only the –SeH group 
is alkylated at low pH (pH 6.5) [26]. As such, we applied 
this finding to identify whether EM23 targeted these active 
sites by performing BIAM alkylating reactions in buffers 
with different pH values.
As shown in Figure 4C, a weaker band intensity 
was observed when the reduced form of TrxR was 
incubated with EM23 prior to BIAM labeling, indicating 
that TrxR was first alkylated by EM23. Notably, at low pH 
Figure 2: Effects of EM23 on caspase 3 and mitochondrial membrane potential (MMP). (A) Western blotting analysis of 
the expression levels of the following: caspases 3, cleaved caspases 3, PARP and XIAP. (B) Effect of EM23 on MMP in CaSki and SiHa 
cells with the treatment of 0, 5, 15, and 20 µM EM23 for 24 h. The MMP were analyzed by flow cytometry after JC-1 staining. Cells with 
MMP loss were gated. All data are representatives of three independent experiments or presented as the mean ± SD of three independent 
experiments. *P < 0.5 and **P < 0.01.
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Figure 3: The role of ROS production in EM23-induced cell apoptosis. (A) EM23-induced ROS production in CaSki and 
SiHa cells treated with 15 µM EM23 for 1-4 h. Cells were stained with DCFH-DA, and analyzed for fluorescence by flow cytometry at 
525 nm. (B) EM23-induced growth inhibition in CaSki and SiHa cells was inhibited by NAC pre-treatment. Cells were pretreated with 
10 mM NAC, and then treated with 15 µM EM23 for 24 h. Cell viability was then analyzed by MTT assay. (C) EM23-induced apoptosis 
was inhibited by NAC pre-treatment. CaSki and SiHa cells were treated as above and index of apoptotic cells were analyzed by flow 
cytometry after Annexin-V-FITC/PI staining. (D) EM23-induced MMP disruption was inhibited by NAC pre-treatment. Cells were treated 
as above and index of MMP were analyzed by flow cytometry after JC-1 staining. All values are presented as the mean ± SD of three 
independent experiments. *P < 0.5 and **P < 0.01.
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(pH 6.5), band intensity weakened dramatically with 
high concentrations of EM23, indicating that C-terminal 
redox-activesite Sec498 can be alkylated by EM23. At 
a high pH (pH 8.5), the band intensity weakened at 
the same extent observed in low pH (pH 6.5) buffer, 
indicating that the TrxR-Sec498 redox-active site is the 
only specific target for EM23 modification.
To further confirm this result, a short TrxR 
C-terminal peptide Ac-Gly-[Cys-Sec]-Gly-NH2 was 
synthesized and reacted with EM23 to determine whether 
EM23 could specifically bind the selenol group of TrxR. 
The representative TOF LC/MS spectrum of this reaction 
products were shown in Figure 4D. The molecular mass 
of the m/z 383.1 ([M+Na]+) and 448.0 ([M+Na]+) signal 
peak exactly matches that of EM23 and the tetrapeptide, 
respectively. The molecular mass signal identified at 
m/z 810.2 ([M+Na]+) showed the distinctive isotopic 
pattern characteristic of selenium (Figure 4D, up 
right), indicating that an equivalent amount of EM23 
covalently bound to the tetrapeptide. However, no signal 
at m/z 1170.4 ([M+Na]+) was detected (data not shown), 
suggesting that there existed no adduct of the tetrapeptide 
bearing two EM23 groups in this reaction. This MS result 
confirmed TrxR-Sec498 redox-active site as the specific 
target for EM23.
Docking simulation between EM23 and the 
active site of TrxR
In order to further investigate the binding modes of 
EM23 with TrxR, molecular docking studies were carried 
out by Surflex-Dock suite implemented in SYBYL 8.0 
software. The results showed that the most energetically 
favorable binding mode of EM23 at the active site of 
TrxR comed into a free binding energy of −5.08 kcal/mol. 
The MOLCAD surface modeling displayed in Fast 
Connolly pattern demonstrated that EM23 extended into 
the pocket of active site of TrxR (Figure 5A). The lactonic 
ring of EM23 was close to the C-terminal Cys497/Cys498 
motif of TrxR (The Sec498 has been substituted by a Cys 
residue in the crystal structure of TrxR [27]). The distances 
of carbonyl motif at the lactonic ring of EM23 between 
backbone NH of Cys497 and Cys498 were 2.01 and 1.95 
Å, respectively, which may allow hydrogen bonding and 
contribute to covalent interactions between EM23 and side 
chain of Cys497 and/or Cys498. Additionally, the oxygen 
atom at the lactonic ring of EM23 forms another hydrogen 
bond with the backbone NH of Gly496.
EM23 inhibits the expression levels of Trx/TrxR 
in CaSki and SiHa cells
The Trx/TrxR system plays a crucial role in both 
cellular redox homeostasis and cell death regulation, and 
is often found over-expressed in cancer. We next examined 
effects of EM23 on Trx and TrxR expression in CaSki and 
SiHa cells. As shown in Figure 6A, Trx protein expression 
was diminished in both cell lines, and was dose-dependent 
in SiHa cells. Interestingly, TrxR expression slightly 
increased with 5 μM EM23 treatment in the CaSki cell 
line, but then decreased dose-dependently with the 15 and 
20 μM treatments. Furthermore, the mRNA expression 
levels of Trx and TrxR were assessed by RT-PCR assay. 
As shown in Figure 6B, 5 μM EM23 treatment resulted in 
an increase of Trx and TrxR mRNA transcription, whereas 
15 and 20 μM downregulated their expression levels in 
both cell lines.
Knock down of Trx or TrxR results in a 
reduction of EM23-induced apoptosis
To directly assess the role of the Trx/TrxR system 
in EM23-induce apoptosis, we utilized siRNAs that 
specifically target either Trx or TrxR, in addition to a 
control siRNA. As shown in Figure 7A, transfection of 
Trx or TrxR siRNA effectively reduced the respective 
protein levels in both cell lines. EM23-induced apoptosis 
in siRNA transfected CaSki and SiHa cells was then 
assessed by Annexin-V-FITC/PI staining and flow 
cytometry analysis. Significantly, knock down of Trx or 
TrxR attenuated EM23-induced apoptosis in both cell lines 
(Figure 7B). These results suggest that targeting the Trx/
TrxR system is essential for EM23-induced apoptosis in 
CaSki and SiHa cells.
EM23 induces activation of ASK1/JNK signaling
The competitive inhibitory effect of reduced Trx 
on ASK1 is one of the important mechanisms by which 
Trx/TrxR system elicits apoptotic resistance in cancer 
cells [28]. ROS-induced apoptosis can be induced by 
the oxidization of Trx, and the subsequent release of 
ASK1, which can then be activated to prompt apoptotic 
signaling through the p38 and JNK pathway [29]. Here, 
we investigated Trx-ASK1 complex formation after 
treatment with 15 μM EM23 by co-immunoprecipitation 
assay. As expected, we found that ASK1 dissociated 
from Trx following EM23 treatment in both cell lines 
(Figure 8A), and consequently gained kinase activity 
sufficient to elicit downstream signal activation, as 
demonstrated by the increase in phosphorylated ASK1 and 
JNK, respectively (Figure 8B). Furthermore, an increase 
in ASK1 protein expression was observed in both cell 
lines after EM23 treatment (Figure 8B). Interestingly, we 
found that extracellular signal-regulated protein kinase 
1/2 (ERK1/2) signaling was also activated after EM23 
treatment, but only in CaSki cells (Figure 8B).
To further investigate the role of these kinases 
in EM23-induced apoptosis, Annexin-V-FITC/PI dual 
staining flow cytometry analysis was used to analyze the 
cellular apoptosis induced by the combination of EM23 
and ASK1 or JNK inhibitor. As shown in Figure 9, the 
ASK1 and JNK inhibitors attenuated EM23-induced 
apoptosis in both cell lines. Notably, the apoptotic ratio 
Oncotarget6796www.impactjournals.com/oncotarget
declined to about 24% and 23%, respectively, in CaSki 
cells, and about 20% and 23%, respectively, in SiHa cells, 
as compared to EM23-only treatment group. These results 
further support the important role for ASK1/JNK signaling 
in EM23-induced apoptosis.
JNK signaling pathway is a crucial downstream 
pathway triggered by the oxidative stress response [30]. As 
such, we investigated the effect of the anti-oxidant, NAC, 
on EM23-induced JNK signaling. As shown in Figure 8C, 
NAC pretreatment blocked EM23-induced JNK activation 
and PARP cleavage, emphasizing the essential role of ROS 
in EM23-induced JNK pathway activation and subsequent 
cell apoptosis.
EM23 induces autophagy and inhibits 
Akt/mTOR signaling pathway
Autophagy-related programmed cell death has been 
observed in the cellular response to several anticancer 
reagents [31]. In our study, we found that treatment 
Figure 4: EM23 inhibited TrxR activity by binding to the selenocysteine site. (A) NADPH-reduced TrxR was incubated with 
various concentrations of EM23 in cell-free system at room temperature for 5 min. TrxR activity was measured by DTNB reduction assay. 
(B) NADPH-reduced TrxR was incubated with10 µM EM23 for 5, 15, 30 and 90 min. TrxR activity was measured by DTNB reduction 
assay. (C) Different concentrations of EM23 were added to reduced TrxR and incubated at room temperature for 1 h, then subjected 
to BIAM alkylation assays. The same amounts of DMSO were added to the control groups. (D) TOF LC/MS analysis of the adduct 
formed by TrxR C-terminal peptide Ac-Gly-[Cys-Sec]-Gly-NH2 and EM23. The m/z signal peaks corresponding to EM23, tetrapeptide of 
C-terminal motif of TrxR and adduct were indicated by arrows, respectively. Up right, the zoomed in signal peak of m/z 810.2. All data are 
representatives of three independent experiments.
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with 15 μM EM23 for 24 h induced autophagy in both 
CaSki and SiHa cells, as demonstrated by the autophagic 
vacuoles observed with electron microscopy (Figure 10A). 
Furthermore, we found that 15 μM EM23 also induced the 
accumulation of LC3-II (Figure 10B), an autophagy-related, 
ubiquitin-like modifier, regarded as an autophagosomal 
marker in mammals cells [32]. These results suggest that 
EM23 induced autophagy in CaSki and SiHa cells.
Figure 5: The binding mode research between EM23 and TrxR by docking simulations. (A) The MOLCAD surface of the 
binding pocket of docked TrxR-EM23 complexes was displayed in Fast Connolly pattern. (B) Binding interactions with selected residues 
of the active site of TrxR for EM23.
Figure 6: Effects of EM23 on the expression levels of Trx/TrxR system. (A) CaSki and SiHa cells were treated with 0, 5, 15 and 
20 µM EM23 for 24 h, and Trx and TrxR expression levels were analyzed by western blotting. (B) The mRNA levels of Trx and TrxR were 
analyzed by RT-PCR; GAPDH was used as an internal control. Data are presented as the mean ± SD of three independent experiments. 
*P < 0.5 and **P < 0.01.
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The Akt/mTOR-mediated signaling cascade is a 
key negative regulator of autophagy [33]. As shown in 
Figure 10C, both Akt and mTOR phosphorylation 
declined in response to EM23 treatment. The 
phosphorylation status of 70S6K and 4E-BP1, 
the substrates of mTOR was then examined [34]. 
It was observed that the phosphorylation level of 
70S6K decreased in both cell lines upon treatment 
with EM23; however, no significant change in 
phosphaorylation was observed for that of 4E-BP1 
(Figure 10C). It is interesting that EM23 only caused 
a slight decrease in phosphorylation level of ribosomal 
protein S6, the downstream target of 70S6K, and had 
no effect on the expression level of S6 (Figure 10C). 
Together, these results indicate the involvement of Akt/
mTOR signaling pathway in EM23-induced autophagy.
EM23-induced autophagy is mediated by ROS 
and promotes apoptosis
Autophagy frequently results from ROS 
accumulation and mitochondria dysfunction [35]. Notably, 
we found that pre-treatment with NAC rescued the 
EM23-induced LC3-II accumulation observed previously 
(Figure 10D), implying that EM23-induced autophagy was 
mediated by EM23-induced ROS accumulation.
To investigate whether EM23-induced autophagy 
imparted a protective or detrimental effect, cells were pre-
treated with 5 mM 3-MA prior to treatment with 15 μM 
EM23. Cell growth and apoptosis were then determined by 
MTT assay and Annexin-V-FITC/PI staining, respectively. 
As shown in Figure 11A, the inhibitory effect of EM23 
on cell growth was weakened by 3-MA treatment in 
Figure 7: Effect of Trx or TrxR knock down on EM23-induced apoptosis. CaSki and SiHa cells were transfected with Trx or 
TrxR siRNA. (A) Protein lysates were prepared 24 h after transfection, and the expression levels of Trx and TrxR were analyzed by western 
blotting. (B) After transfection for 24 h, CaSki and SiHa cells were treated with 15 µM EM23 for another 24 h. Apoptotic cells were then 
analyzed by flow cytometry after Annexin-V-FITC/PI staining. Data are presented as the mean ± SD of three independent experiments. 
*P < 0.5 and **P < 0.01.
Oncotarget6799www.impactjournals.com/oncotarget
both cell lines. These results were further verified by 
Annexin-V-FITC/PI staining and flow cytometry analysis 
(Figure 11B). These data indicate that EM23-induced 
autophagy indeed had a detrimental effect on CaSki and 
SiHa cells, and resulted in apoptosis.
DISCUSSION
The Trx/TrxR system, composed of TrxR, Trx, 
and NADPH, is the major protein disulfide reduction 
system of the cell [36]. The mammalian TrxR is a Sec-
containing oxidoreductase previously identified as a 
chemotherapeutic target in cancer cells and contains a 
highly reactive selenocysteine susceptible to electrophilic 
attack, which makes TrxR a suitable target for anticancer 
drug development. To date, many synthetic and natural 
therapeutic compounds that exhibit anticancer properties 
have been classified as TrxR inhibitors. Prominent 
examples include platinum drugs [37], gold compounds 
[38], arsenic trioxide [39], curcumin [12], mercury [40], 
motexafin gadolinium [41], nitroaromatic compounds 
[42], and flavonoids [13], all of which have been evaluated 
either as novel cancer treatments or adjuncts to existing 
therapies. Our findings demonstrate that EM23 inhibits the 
reduction activity of TrxR in cell-free systems (Figure 4A), 
and is also sufficient to induce the downregulation of Trx 
and TrxR in CaSki and SiHa cells (Figure 6). 
Trx and TrxR have important roles in enzymatic 
reductions and resistance against oxidative stress [43]. 
Generally, the inhibition of TrxR activity will directly 
influence the redox functions of Trx, leading to a 
disruption in cellular redox homeostasis. Disrupted redox 
status can activate the mitochondria-dependent apoptosis 
pathway frequently observed in several representative 
SLs, including helenalin [44], costunolide [45], and 
parthenolide [46]. Here, we found that EM23 inhibited cell 
growth, and facilitated apoptosis by promoting caspase and 
PARP cleavage, as well as disruption of Δψm (Figure 2). 
We also found that ROS accumulation was involved in 
EM23-induced apoptosis in CaSki and SiHa cells, as the 
ROS scavenger, NAC, almost completely reversed these 
effects (Figure 3).
It is generally believed that one of the most 
important molecular mechanisms for SL-induced 
apoptosis involves the conjugation of their unsaturated 
carbonyl structures to sulfhydryl groups. TrxR represents 
a potential target of EM23 because its C-terminal active 
site contains a highly reactive selenocysteine (Sec498) 
residue essential for the catalytic activity of TrxR. The 
ability of EM23 to inhibit the TrxR activity identifies it 
as a molecular target of EM23 (Figure 4). BIAM-labeling 
assays identified the C-terminal Sec498 as the primary 
site of alkylation by EM23, a result further confirmed by 
TOF LC-MS analysis of adduct of the C-terminal redox-
active motif of TrxR by EM23 and molecular docking 
stimulation (Figure 5). Notably, the lactonic ring of EM23 
was close to the redox-active site of TrxR as demonstrated 
by the docking stimulation, which may allow the covalent 
interactions occurring between EM23 and the Cys497 and 
Sec498 simultaneously. Nevertheless, it is interesting that 
both BIAM-labeling assays and TOF LC-MS analysis 
demonstrated the selective alkylation of EM23 towards 
only the Sec498, but not the neighboring Cys497. This may 
be that the reactivity of the selenocysteine to electrophiles 
Figure 8: Effects of EM23 on ASK1, JNK and ERK signaling pathways. (A) CaSki and SiHa cells were treated with 15 µM 
EM23 for 8 h. ASK1-Trx complex was then precipitated by Protein A beads conjugated with Trx antibodies and analyzed by western 
blotting with ASK1 and Trx antibodies. (B) CaSki and SiHa cells were treated with 0, 5, 15 and 20 µM EM23 for 24 h, the expression levels 
of ASK1, p-ASK1, JNK, p-JNK, ERK and p-ERK were analyzed by western blotting analysis. (C) Effect of ROS scavenger NAC on JNK 
signaling pathway and PARP. CaSki and SiHa cells were pre-treated with 10 mM NAC followed by 15 µM EM23 for 24 h. Protein lysates 
were prepared and expression levels of JNK, p-JNK and PARP were analyzed by western blotting analysis. All data are representatives of 
three independent experiments.
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is greater than the cysteine, which was calculated to 
be approximately 1000 times difference [47]. To our 
knowledge, our study is the first report that SL compound 
inhibits TrxR activity by specifically targeting the 
C-terminal redox-active site Sec498. 
TrxR inactivation can lead to an imbalance of 
cellular redox state and regulation of Trx/TrxR system-
related cell signal cascades. ASK1, a member of the 
MAPK kinase kinase family, is an important signaling 
molecule regulated by Trx/TrxR system. Under normal 
conditions, inactivated ASK1 is bound to reduced 
Trx; however, upon oxidative stress, ASK1 activates 
when Trx redox state shifts to the oxidized form [48]. 
Indeed, our results demonstrate that ASK1 is released 
from Trx following EM23 treatment (Figure 8A), 
and subsequently activates, as demonstrated by the 
increase in phosphorylation at Ser83 of ASK1. JNK, 
one of the signal mediators downstream of ASK1, is 
classified as stress-activated kinase and is activated by 
a variety of stressors, including oxidative stress and 
chemotherapeutic drugs [30]. The ROS-ASK1-JNK 
signaling axis has important roles in oxidative stress-
induced cell death and mostly required for oxidative 
stress-induced apoptosis. JNK has been found to 
regulate both pro-apoptotic and anti-apoptotic proteins, 
such as c-Jun, 14-3-3, and Mcl-1 [49], that play key 
roles in mitochondria-dependent apoptosis. In addition, 
pretreatment with ASK1 and JNK-specific inhibitors, 
or expression of dominant negative ASK1 and JNK 
mutants, hindered cell apoptosis induced by various 
types of stress [50–52], which is in agreement with our 
observations (Figure 9), suggesting that EM23-induced 
apoptosis is dependent on the ASK1/JNK pathway. 
However, pro-apoptotic JNK activation could also be 
regulated by other MAP3Ks, in addition to ASK1, such 
as MEKK1 and MLK3. As such, further studies are 
needed to determine whether ASK1 plays a critical role 
in EM23-induced JNK activation.
Figure 9: Effects of ASK1 and JNK inhibitor on EM23-induced apoptosis. Cells were pre-treated with 0.6 and 0.2 µM ASK1 
and JNK inhibitor, respectively, and then incubated with 15 µM EM23 for 24 h. Index of apoptosis in CaSki (A) and SiHa (B) cells were 
analyzed by flow cytometry after Annexin-V-FITC/PI staining. Data are presented as the mean ± SD of three independent experiments. 
*P < 0.5 and **P < 0.01.
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Sustained exposure to oxidative stress is potentially 
very harmful to cells. Among several intracellular 
signaling pathways elicited by oxidative stress, the MAPK 
cascade plays pivotal roles in regulating oxidative stress-
induced cell death [30]. In our study, ROS scavenging, 
which is upstream signal of MAPK, resulted in a reduction 
of JNK activation and PARP cleavage (Figure 8C), 
highlighting the important roles of ROS in EM23-induced 
activation of JNK signal.
Many cancer cells have high levels of expression 
of Trx and TrxR; therefore, it is not surprising that knock 
down of TrxR in a mouse lung cancer cell line nearly 
abolished their capacity to form xenograft tumors [7]. 
This seems contradictory to our founding. Interestingly, 
a reduction of TrxR activity was observed in HeLa cells 
following both siRNA-mediated knock down or treatment 
with a therapeutic inhibitors; however, only the therapeutic 
agents, but not the siRNA, resulted in increased oxidative 
stress [53]. This indicates that residual TrxR1 activity 
remaining upon TrxR1 knock down could still be enough 
to counteract ROS. In addition, some compounds can also 
convert TrxR to a ROS-generating enzyme and induce cell 
apoptosis, in direct contrast to its usual role [42, 54, 55]. 
Furthermore, another report found that the TrxR system 
was required for caspase 3 activation and apoptosis 
[56], whereas we found that EM23-induced apoptosis 
was partially dependent on a normal level of TrxR/Trx. 
Nevertheless, more evidence is needed to illuminate 
the precise mechanism of TrxR/Trx-dependent EM23-
induced apoptosis, including the effect of TrxR or Trx 
knockdown on EM23-induced ROS accumulation, caspase 
3 activation, and the MAPK pathway activation.
The phosphoinositide 3-phosphate kinase (PI3K)/
Akt/mTOR signaling pathway and the Ras/Raf1/ERK1/2 
pathway are known to regulate autophagy in the cellular 
response to nutrient starvation [31]. The PI3K/mTOR 
Figure 10: EM23 induced autophagy and inhibited Akt/mTOR signaling pathway in CaSki and SiHa cells. 
(A) Microstructure of cells treated with 15 µM EM23 for 24 h; transmission electron microscopy shows multiple vacuoles. (B) Western 
blotting analysis of expression levels of LC3 I/II in CaSki and SiHa cells treated with 0, 5, 15, and 20 µM EM23 for 24 h. (C) The 
expression levels of p-Akt, Akt, p-mTOR, mTOR, p-4E-BP1, p-P70S6K, p-S6, and S6 in CaSki and SiHa cells. Cells were treated with 0, 5, 
15, and 20 µM EM23 for 24 h and then subjected to western blotting analysis. (D) CaSki and SiHa cells were pretreated with 10 mM NAC 
and treated with 15 µM EM23 for 24 h, protein lysates were then prepared and the expression levels of LC3 I/II were analyzed by western 
blotting analysis. All data are representatives of three independent experiments.
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and ERK1/2 pathways negatively and positively regulate 
autophagy, respectively. Accumulating evidence has 
shown that autophagy is activated in response to various 
therapeutic agent treatments, including suberoylanilide 
hydroxamic acid [57], vitamin K2 [58], Lapatinib [59], 
and ursolic acid [60]. Furthermore, curcumin treatment 
induced autophagic cell death in human malignant 
glioma cells by inhibiting the mTOR/p70S6K and 
activating the ERK1/2 pathways simultaneously [33], 
whereas triterpenoid B-group soyasaponins worked by 
inhibiting AKT signaling and enhancing ERK activity 
[61]. Thus, Akt/mTOR inhibition and ERK activation 
are probably common mechanisms of autophagy 
induced by anticancer agents. In addition, recent studies 
have shown that LC3 is processed by a specific protein 
activation/conjugation system to form autophagosomal 
membranes during autophagy [62]. In this study, we 
found the reduction of Akt/mTOR signaling and the 
enhanced conversion of LC3-I to LC3-II occurred in 
a dose-dependent manner (Figure 10B and 10C). It is 
interesting that a significant decrease was observed 
in the phosphorylation level of P7S6K with EM23 
treatment, whereas there was no obvious change in 
that of 4E-BP1 in spite of the decrease of mTOR 
phosphorylation (Figure 10C). It can be explained that 
the selectivity and sensitivity of mTOR for its substrates 
may be dependent on the integrity and configuration of 
mTOR and a change in the phosphorylation status of 
one mTOR substrate does not necessarily correlate with 
changes in others [34]. Yip et al. have also reported that 
rapamycin strongly declined P7S6K phosphorylation, 
whereas its effect on 4E-BP1 was more variable [63]. In 
addition, it should be noted that EM23 caused a slighter 
decrease in phosphorylation level of S6 than that of 
70S6K. This may be due to the other kinases such as 
RSK that involve in regulating the phosphorylation of 
S6 [64]. Although autophagy can be stimulated in many 
tumor cells under therapeutic agent-induced stress, 
the exact role of autophagy in cancer cell death is still 
not clear. Notably, many anticancer drugs, including 
bortezomib, resveratrol, sorafenib, histone deacetylase 
inhibitors, chloroquine, sulforaphane, and mTOR 
inhibitors, similarly engender autophagic cell death 
[65]. Currently, induction of autophagic cell death has 
Figure 11: Effects of 3-MA on EM23-induced cell growth inhibition and apoptosis. CaSki and SiHa cells were pre-treated 
with 5 mM 3-MA for 1 h, followed by 15 µM EM23 for 24 h. Cell viability was analyzed by MTT assay (A) and the apoptotic index cells 
were analyzed by flow cytometry after Annexin-V-FITC/PI staining (B). All data are presented as the mean ± SD of three independent 
experiments. *P < 0.5 and **P < 0.01.
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been regarded as a potential method for cancer therapy. 
Consistent with these findings, we found that EM23-
induced autophagy had an apoptosis-promoting effect 
in both cell lines (Figure 11). 
While the precise mechanism of autophagy remains 
unclear, mitochondrial-originated ROS was thought to 
play a central role in the induction of autophagy, and 
could be significantly blocked by NAC, a ROS scavenger. 
In this study, we found that LC3-II accumulation 
was blocked by NAC pre-treatment (Figure 10D). 
It is worthy noted that inhibition of ROS by NAC is able 
to decrease not only ROS level but also mTOR activity 
[66]. To a certain degree, the pre-treatment of NAC 
might contribute to EM-23-induced autophagy and the 
following apoptosis. 
Interestingly, recent investigations have shown that 
ginseng metabolite [67], isoorientin [35], polygonatum 
cyrtonema [68]-induced autophagy results from ROS 
accumulation and subsequent activation of the JNK 
signaling. In this studies, we found that EM23-induced 
accumulation of ROS occurred upstream of JNK 
activation (Figure 8C), implying a causal role of JNK 
signaling in EM23-induced autophagy. However, more 
evidence is needed to solidify this mechanism.
In summary, our study demonstrated that EM23 was 
an efficient anticancer agent in vitro, and was sufficient 
to induce apoptosis in two human cervical cancer cell 
lines, CaSki and SiHa (Figure 12). EM23 attenuated 
TrxR activity by binding to the selenocysteine site of 
TrxR and inhibited the expression levels of Trx/TrxR to 
facilitate ROS accumulation, which played a central role 
in EM23-induced apoptosis. In addition, inhibition of 
Trx/TrxR system resulted in the dissociation of ASK1 
from complex with Trx and activation of downstream 
JNK signaling pathway, which contributed to EM23-
induced apoptosis. ROS also facilitated the activation of 
JNK signaling pathway. Furthermore, EM23 inhibited 
Akt/mTOR ribosomal protein-signaling pathway and 
induced autophagy, which was proapoptotic and mediated 
by ROS. This report represents the first comprehensive 
analysis of mammalian TrxR and cellular signaling events 
in response to the treatment of EM23 in human cervical 
Figure 12: EM23-mediated intracellular signaling elicits apoptosis in human cervical cancer cells.
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cancer cells, provides a possible molecular mechanism 
for the anticarcinogenic effects of SLs and emphasizes the 
potential application of EM23 as a therapeutic agent for 
human cervical cancer.
MATERIALS AND METHODS
Cell culture and reagents
The cells of the following were purchased from the 
Cell Bank of the Chinese Academy of Sciences (Shanghai, 
China): lung cancer cell line A549; human breast cancer 
cell line MCF-7; human esophageal cancer cell lines TE-
1, EC109, and EC9706; human cervical cancer cell lines 
CaSki and SiHa; and human leukemia cell lines HL-60 
and K562. Both HL-60 and K562 cell lines were cultured 
in RPMI 1640 medium (Life Technologies, USA) and 
the other cell lines were cultured in DMEM (Gibco; 
Carlesbad, CA, USA). All the medium were supplemented 
with 10% fetal bovine serum (FBS, Gibco), 100 U/mL 
penicillin, and 100 µg/mL streptomycin. The cells were 
grown at 37°C in a humidified 5% CO2 atmosphere.
TrxR was purified from porcine brains, as 
described by Cheung et al. [69]. EM23 was isolated 
from Elephantopus mollis as described previously 
[70]. Ac-Gly-[Cys-Sec]-Gly-NH2 was synthesized by 
Shanghai Tauto Biotech Co, Ltd. (Shanghai, China) 
as described by Pratesi et al. [71]. Triphosphopyridine 
nucleotide reduced tetrasodium salt (NADPH), N-acetyl-
l-cysteine (NAC), Dimethyl sulfoxide (DMSO), 
5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethyl-imidacarbocyanine 
iodide (JC-1), 2′,7′-dichlorofluoresceindiacetate (DCFH-
DA), 3-methyladenine (3-MA) autophagy inhibitor, 
3-(4,5-dimetrylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT), 5,5′-dithio-bis (2-nitrobenzoid acid) 
(DTNB), and glutaraldehyde were purchased from Sigma 
(St. Louis, MO, USA). JNK inhibitor II (SP600125) and 
ASK1 inhibitor (ERK kinase kinase 5 inhibitor) were 
purchased from Merck Millipore (Bellerica, MA, USA). 
Biotin-conjugated iodoacetamide (BIAM), propidium 
iodide (PI), dithiothreitol (DTT), and RNase were 
purchased from Beyotime (Shanghai, China).
Antibodies against ASK1, p-ASK1 (Ser83), 
GAPDH, caspase 3, cleaved caspase 3, X-linked inhibitor 
of apoptosis (XIAP), PARP, JNK, p-JNK1/2 (Thr183/
Tyr185), ERK, p-ERK (Thr202/Tyr204), p-4E-BP1, 
p-P70S6K, LC3, mTOR, p-mTOR (Ser2448), S6, and 
p-S6 (Ser235/236) were purchased from Cell Signaling 
Technology (CST; Beverly, MA, USA). Trx, TrxR, and 
horseradish peroxidase-conjugated secondary antibodies 
were purchased from Santa Cruz Biotechnology (Dallas, 
TX, USA). 
Cell growth inhibition assay
EM23-induced growth inhibition was measured by 
MTT assay. CaSki and SiHa cells in log-phase growth 
were seeded in 96-well plates (6 × 103 cells per well) and 
allowed to attach for about 12 h. Cells were then treated 
with a range of EM23 concentrations. The medium was 
removed 24 h later, and 50 µL of the same medium 
containing 5 mg/mL MTT was added to each well, and 
incubated for another 4 h. The medium was removed 
again, and 100 µL DMSO was added to each well and 
incubated for 15 min. Cell viability was determined by the 
absorbance at 570 nm as measured by microplate reader 
(Bio-Rad; Hercules, CA, USA), and the IC
50
 values of 
EM23 for each cell line were calculated using Origin 8 
software (OriginLab, Northampton, MA USA).
Flow cytometry analysis of cell cycle arrest and 
apoptosis
CaSki (3.0 × 105 cells/mL) and SiHa (4.0 × 105 cells/
mL) cells were seeded in 6-well Petri dishes the day prior 
to the experiment. Cells were treated with 5, 15, or 20 µM 
EM23 for 24 h, then harvested, washed twice with ice-
cold PBS, and fixed in 70% ethanol at −20°C overnight. 
Fixed cells were washed once with ice-cold PBS and 
re-suspended in 1 mL of staining reagent containing 
100 mg/mL RNase and 50 mg/mL PI for 25 min in the 
dark. To assess apoptotic ratio, harvested cells were 
stained with Annexin-V-FITC/PI (KeyGEN; Nanjing, 
China) according to the manufacturer’s instructions. 
Cell cycle arrest and apoptosis were analyzed by flow 
cytometry (BD FACSCalibur; Franklin Lakes, CA, USA). 
Fluorescence of PI and Annexin-V-FITC was monitored at 
630 nm and 525 nm, respectively.
Evaluation of mitochondrial membrane potential 
(MMP)
CaSki (3.0 × 105 cells/mL) and SiHa (4.0 × 105 
cells/mL) cells were seeded in 6-well Petri dishes the day 
prior to the experiment. After treatment with 5, 15, or 
20 µM EM23 for 24 h, cells were harvested, washed twice 
with ice-cold PBS, and incubated with JC-1 (10 µg/mL) in 
the dark for 15 min at 37°C. Cells were then washed three 
times with ice-cold PBS and analyzed by flow cytometry 
using emission wavelengths of 590 nm and 525 nm.
Immunoblotting
After treatment with 5, 15, or 20 µM EM23 for 24 
h, cells were harvested and washed twice with ice-cold 
PBS. For immunoblotting analysis, cells were lysed in 
RIPA buffer (Beyotime; Shanghai, China) for 30 min 
on ice, and then centrifuged at 12,000 g for 15 min. 
Supernatants were collected and protein was denatured 
at 100°C for 5 min. Equal amounts of protein were then 
separated on SDS-PAGE gels and transferred to PVDF 
membranes. Membranes were blocked with 5% nonfat 
milk at room temperature for 1 h, incubated with primary 
antibodies overnight at 4°C, and then with a horseradish 
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peroxidase-conjugated secondary antibody at room 
temperature for 1 h. Protein bands were visualized by 
enhanced chemiluminescence (Millipore).
Immunoprecipitation
For immunoprecipitation, equal amounts of protein 
from lysates prepared as above were co-incubated with 
Trx primary antibody and protein A magnetic beads 
(Santa Cruz) at 4°C overnight. The pellet was washed 
five times with ice-cold NP40 (Beyotime), resuspended 
in SDS-loading buffer (Beyotime), and analyzed 
by immunoblotting with Trx and ASK1 antibodies, 
respectively.
Determination of ROS production
CaSki (3.0 × 105 cells/mL) and SiHa (4.0×105 
cells/mL) cells were seeded in 6-well Petri dishes. After 
the treatment with 15 µM EM23 for 1–4 h, cells were 
incubated with 10 µM DCFH-DA for 15 min in the dark, 
washed three times with ice-cold PBS, and DCFH-DA 
fluorescence was measured at 525 nm by flow cytometry 
on a BD FACSCalibur.
Quantitative real-time PCR
CaSki (3.0 × 105 cells/mL) and SiHa (4.0 × 105 
cells/mL) cells were seeded into 6-well plates. Cells 
were harvested following treatment with 5, 15, and 
20 µM EM23 for 24 h, and total RNA was extracted using 
Pure Link™ Viral RNA/DNA Kits (Invitrogen). The 
quantitative PCR of Trx and TrxR mRNA was performed 
using SYBR Green Real-time PCR Master Mix (Toyobo) 
as described by the manufacturer. Gene-specific primer 
pairs used in this study were as follows: TrxR sense 
5′-TGTTGAATGAACAACTGTGC-3′ and TrxR antisense 
5′-TCCTCAGCCAGTACATTGAC-3′, Trx sense 
5′-CATAACCAGCCATTGGCTATT-3′ and Trx antisense 
5′-GCATAATGTTTATTGTCACG-3′, GAPAH sense 
5′-CACCCAGAAGACTGTGGATGG-3′ and GAPDH 
antisense 5′-GTCTACATGGCAACTGTGAGG-3′.
Inhibition of TrxR in cell-free systems
TrxR (50 nM) and NADPH (200 µM) were 
incubated in 100 mM potassium phosphate buffer 
(pH 7.4) supplemented with 2 mM EDTA at room 
temperature for 4–5 min. Various concentrations of EM23 
were added to the mixture and incubated for another 5 min. 
The reaction was started and TrxR activity was monitored 
by the increase in absorbance at 412 nm in the initial 80s 
after the addition of 2 mM 5,5′-dithiobis (2-nitrobenzoic 
acid) acid (DTNB), where TrxR mediated the reduction of 
DTNB into two molecules of 2-nitro-5-thiobenzoate anion 
(TNB) in the presence of NADPH. TrxR activity was 
expressed as percentage of control. For time-dependent 
incubation, TrxR was incubated with 10 µM EM23 in 
the above assay mixture for various time periods. TrxR 
activity was measured by DTNB reduction assay and was 
expressed as a percentage of the corresponding controls in 
the absence of EM23.
BIAM-labeling assay
TrxR was incubated with EM23 in 20 mM Tris-
HCl, 1 mM EDTA pH 7.5, and 200 µM NADPH at 
room temperature for 1 h, and then subjected to BIAM 
alkylation in buffers containing 100 mM Tris-HCl and 
1 mM EDTA at pH 6.5 or 8.5 for 30 min. The protein 
samples were then denatured in SDS sample buffer (CST). 
BIAM-labeled TrxR was separated by SDS–PAGE, and 
detected with horseradish peroxidase (HRP)-conjugated 
streptavidin (Beyotime) and enhanced chemiluminescence 
(Millipore).
Mass spectrometry analysis
Ac-Gly-[Cys-Sec]-Gly-NH2 tetrapeptide, mimicking 
the TrxR C-terminal redox-active site, was reduced by DTT 
prior to its addition to a reaction with 1.4 equivalents of 
EM23 for 30 min at room temperature. The reaction products 
were analyzed with an Agilent 6210 TOF LC/MS system 
(Agilent, Santa Clara, CA, USA) in positive ion mode.
Molecular docking studies
Docking studies were performed using the molecular 
modeling software package SYBYL 8.0 (Tripos, USA). 
The ligand EM23 was charged with Gasteiger-Hückel and 
minimized by using the Powell’s method with standard 
Tripos force field with a 0.005 kcal/(mol*Å) gradient. The 
maximum number of iterations during minimization was 
1000. The minimum-energy structure was used for the 
subsequent docking calculations. The initial 3D structure 
of TrxR used for docking studies was retrieved from the 
Protein Data Bank (PDB) with accession code 2ZZB. The 
Surflex-Dock program implanted in SYBYL was used for 
the docking calculations. To generate the Surflex-Dock 
control file, the crystallographic ligand was extracted from 
the binding site of TrxR, and the residues within a 5.0 Å 
radius around the enzyme were defined as the active site. 
MOLCAD surface displayed in Fast Connolly pattern was 
generated for visualizing the binding mode of the docked 
protein-ligand complexes.
Transfection with small interfering RNA 
(siRNA)
Trx and TrxR siRNA were purchased from Santa 
Cruz. CaSki and SiHa cells were seeded at 2 × 105 per well 
in 2 mL antibiotic-free DMEM medium supplemented 
with FBS. Cells were transfected with 0.4 µg siRNA using 
Lipofectamine 2000 (Invitrogen; Carlesbad, CA, USA) per 
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the manufacturer’s protocols. After transfection for 24 h, 
cells were incubated with 15 µM EM23 for 24 h, and then 
collected for analysis by flow cytometry and western blot.
Transmission electron microscopy
Cells treated with 15 µM EM23 for 24 h were 
harvested, washed twice with ice-cold PBS, resuspended 
in glutaraldehyde, and incubated for 20 min at room 
temperature. Ultrathin slices were prepared and examined 
under a Hitachi 7000 transmission electron microscope 
(Tokyo, Japan).
Statistical analysis
All data are reported as the mean ± SD of three 
independent experiments performed in triplicate. The 
differences between two treatment groups were analyzed 
by two-tailed unpaired Student’s t test; three or more 
groups were compared by one-way ANOVA multiple 
comparisons. P-values of < 0.05 were regarded as 
statistically significant.
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